Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines

MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108. doi: 10.15585/mmwr.mm6703a5.


On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01B), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2-6 months apart (1). On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years.

MeSH terms

  • Advisory Committees
  • Aged
  • Herpes Zoster / prevention & control*
  • Herpes Zoster Vaccine / administration & dosage*
  • Humans
  • Immunization Schedule
  • Immunocompetence
  • Middle Aged
  • Practice Guidelines as Topic*
  • United States
  • United States Food and Drug Administration
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Synthetic / administration & dosage


  • Herpes Zoster Vaccine
  • Vaccines, Attenuated
  • Vaccines, Synthetic